Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva

BASF’s Personal Care business launches Ameriflor Calm

Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity

Merck unveils new HIV treatment and prevention data at EACS 2025

Merck will showcase results in innovative solutions in HIV treatment and prevention

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine

AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease

If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option

DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland

The new site enables end-to-end production of viral vector gene therapies